{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Percentage of patients with who experienced disease progression on study. PD is \\>25% increase in serum IgM from baseline with an absolute increase of at least 500 mg/dL, or progression of clinically significant disease related symptoms. Death from any cause or initiation of a new anti-neoplastic therapy will also be considered a progression event. An increase of 1 cm in any axis for adenopathy, or 2 cm in the craniocaudal axis of the spleen will be considered evidence of progression of extramedullary disease. Development of Bing Neel syndrome, or other extramedullary disease manifestations, as well as disease transformation will be considered as progressive events.","groups":[{"description":"\\-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle.\n\nDasatinib: Oral Study Drug(s):\n\n* Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day.\n* This will continue for up to 24 cycles.\n\nDasatinib: Oral, daily, dosing per protocol, once a day for cycle","id":"OG000","title":"Dasatinib"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From first dose through disease progression, up to 2 years from baseline","title":"Progressive Disease Rate","type":"SECONDARY","unitOfMeasure":"Participants"}